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www.jacctctabstracts2014com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM21.3% with cLVR; P¼0.05; Table). Rates of repeat hospitalization did not differ
between groups. Risk of myocardial infarction was greatest (3.5% vs 0.9% with
cLVH; P¼0.001) and stroke lowest (1.5 vs 6.2% with cLVH; P¼0.003) in the eLVH
goup at 1-year. Functional class and 6-minute walk distance were worst at all time
points in patients with baseline cLVH.Table. Clinical outcomes after TAVR stratiﬁed by baseline LV geometry.




All-cause Death 20.70% 14.6%* 18.00% 18.60% 0.04
Cardiac Death 10.80% 5.9%* 8.80% 8.60% 0.02
Repeat
hospitalizations
14.60% 15.40% 16.00% 20.50% 0.22
Stroke 3.10% 4.00% 5.60% 1.5%* 0.02
Myocardial infarction 0.60% 1.10% 0.70% 3.5%** 0.002
1-Year Outcomes
All-cause Death 26.20% 21.30% 25.10% 26.80% 0.08
Cardiac Death 12.90% 9.20% 11.10% 10.80% 0.19
Repeat
hospitalizations
20.60% 19.10% 21.30% 25.00% 0.2
Stroke 3.90% 4.40% 6.20% 1.5%** 0.01
Myocardial infarction 1.00% 1.70% 0.90% 3.5%** 0.01
*Pairwise comparison P<0.0167 (Bonferroni-adjusted).
** Pairwise comparison P<0.005.Conclusions: In patients with symptomatic severe AS, geometric patterns of LV
remodeling at baseline are associated with differential risk of death, stroke, and
myocardial infarction after TAVR.
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Background: Transcatheter Aortic Valve Replacement (TAVR) has being increas-
ingly offered in low and intermediate surgical risk patients with severe aortic stenosis
(AS). The OBSERVANT study aims to describe 12-month clinical outcomes of a
large series of propensity-matched patients at low or intermediate risk undergoing
transfemoral TAVR and surgical aortic valve replacement (SAVR).
Methods: OBSERVANT is an observational prospective multicenter cohort study,
enrollingASpatients undergoing SAVRor TAVR.Data onmortality, hospitalizations at
follow-up andmajor complicationswere derived fromadministrative reports. Propensity
score method was applied to select two groups with similar baseline characteristics.
Results: The unadjusted enrolled population (N¼7,618) comprises 5,707 SAVR
patients and 1,911 TAVR patients. Matched population comprised a total of 1,300
patients (650 patients for each group). A population at intermediate risk was selected
(mean logistic EuroSCORE 10.29.2% vs. 9.57.1%, SAVR vs. transfemoral
TAVR; p¼0.104). Thirty-day mortality was 3.8% and 3.2% for SAVR and TAVR
(p¼0.546). The incidence of stroke and acute myocardial infarction was similar in the
two groups, whereas a higher requirement for blood transfusion was reported across
the surgical cohort (. 3.63.6 vs. 2.32.2 red blood cells units; p¼0.002). A higher
incidence of major access site complications (0.5% vs. 7.9%; p< 0.001) and per-
manent pacemaker implantation (3.6% vs. 15.5%; p< 0.001) were reported in the
TAVR group. 12-month mortality was 13.1% and 12.6% for SAVR and TAVR
(p¼0.313). Data regarding re-hospitalizations and other major complications at
12 months will be available for the presentation of the abstract
Conclusions: The results of this study show that transfemoral TAVR and SAVR have
comparable mortality outcomes at 12-month in patients with severe AS and at inter-
mediate surgical risk. At 30-day SAVR was associated with a higher risk for blood
transfusion, whereas TAVR showed a signiﬁcantly increased rate of vascular damage,
and permanent pacemaker requirement.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/VaTCT-688
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Background: Recent reports have documented the early utility of transcatheter valve
implantation within failed surgical bioprosthesis for patients at high risk for surgical
re-intervention. We sought to report outcomes of valve-in-valve (VIV) procedures at
one year, and to understand whether residual gradients impact clinical outcomes and
left ventricular mass regression (LVMR).
Methods: Patients with severe symptomatic stenosis, regurgitation, or mixed disease
of surgical bioprosthetic aortic valves who were at very high risk for repeat aortic
valve replacement surgery (mortality/morbidity >50%) were prospectively enrolled in
the multicenter PARTNER II VIV registry using the Sapien XT device.
Results: A total of 96 patients underwent VIV procedures. At baseline, the mean age
was 80.1 9.3 years and 45.8% of patients were female. The Society of Thoracic
Surgeons predicted risk of operative mortality was 9.9  5.1%. Labelled surgical
valve sizes (mm) were 21 in 31.5%, 23 in 41.3%, and >23 in 27.2%. The 23-mm XT
valve was implanted in 76.6% and the 26-mm valve in 23.4%.The predominant he-
modynamic manifestation of surgical aortic valve failure was classiﬁed as prosthetic
stenosis in 61%, regurgitation in 17% or combined steno-regurgitation in 22%. Thirty-
day all-cause mortality was 7.7%. One year all-cause mortality, rehospitalization,
stroke, adverse events and hemodynamic performance of the Sapien XT device uti-
lized for VIV therapy including residual gradients and LVMR are currently being
adjudicated and will be available at time of presentation.
Conclusions: Transcatheter aortic valve implantation within existing tissue valves is a
viable therapeutic modality for the management of high-risk patients with senescent
bioprosthetic devices. While short-term safety has been demonstrated, mid-term clinical
outcome and hemodynamic performance data are needed to fully understand the po-
tential of VIV procedures to alter the therapeutic landscape. In particular, the effect of
residual gradients and their impact on clinical outcomes and LVMR remain unknown.
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Background: The United Kingdom Transcatheter Aortic Valve Implantation Registry
(U.K. TAVI Registry) reported 30-day and 1-year survival of 92.9% and 78.6%
respectively in patients undergoing TAVI. Few data are available on outcome beyond
3 years in any notable number of patients. The aim of this study was to report clinical
outcome 3- and 5-years after TAVI, regardless of technology or access route, using
data from UK TAVI registry
Methods: The U.K. TAVI Registry captured all TAVI procedures performed within
the UK from 01/01/2007 to 31/12/2009. Data were collected prospectively on 870
patients. Mortality status was reported as of July 2013, and mortality tracking was
achieved in 95.2% patients. Minimum follow-up was 3.54 years, maximum follow-up
was 6.36 years.
Results: Survival at 3-years and 5-years was 61.6% and 48.4% respectively. At 3-
years, survival was independently adversely affected by atrial ﬁbrillation (p¼0.018),
chronic obstructive pulmonary disease (COPD) (p¼0.034), renal dysfunction (Cr
>200mmol/L) (p¼0.008) and baseline Euroscore (18.45) (p0.012). At 5-years,
survival was independently adversely affected by age (p¼0.001), diabetes (p¼0.01),
atrial ﬁbrillation (0.009), chronic obstructive pulmonary disease (COPD) (p¼0.022),
renal dysfunction (Cr >200mmol/L) (p¼0.002), and baseline Euroscore (18.45)
(p0.026). Valve type (Edwards vs. Medtronic), access route (transfemoral vs. non-
transfemoral), or procedural complications (moderate/severe paravalvular aortic
regurgitation, major vascular complications, and need for permanent pacing) did not
predict mortality at either 3- or 5-years.
Conclusions: Almost half patients undergoing TAVI were alive after 5 years. Long-
term survival after TAVI is determined by intrinsic patient factors (age, diabetes, AF,
respiratory disease, renal impairment). Neither procedural nor device-related factors
were independent predictors of long-term mortality.lvular disease - Aortic: TAVR B201
